3.2 Lipid Testing Methods, Direct Assays & the Friedewald Equation

3.2 Lipid Testing Methods, Direct Assays & the Friedewald Equation

[!NOTE] ASCP Exam Focus: Clinical laboratory technologists must be thoroughly proficient in: (1) the multi-step enzymatic reactions used to measure Total Cholesterol and Triglycerides, including specific chemical interferences; (2) the physiological basis and resolution of endogenous glycerol interference (pseudohypertriglyceridemia); (3) the exact mathematical calculation and three strict failure limitations of the Friedewald equation; and (4) the clinical indications for direct homogeneous LDL-C assays versus Non-HDL cholesterol.

---

The Clinical Lipid Profile and Pre-Analytical Requirements

The standard lipid profile comprises four core measurements: Total Cholesterol (TC), Triglycerides (TG), High-Density Lipoprotein Cholesterol (HDL-C), and Low-Density Lipoprotein Cholesterol (LDL-C) (either calculated or directly measured). From these, secondary atherogenic markers are derived, including Non-HDL Cholesterol and estimated VLDL-C.

+---------------------------------------------------------------------------------------------------------+
|                                 Standard Adult Lipid Profile Reference Values                           |
+---------------------------------------------------------------------------------------------------------+
| Analyte                    | Optimal / Desirable            | Borderline High        | High / Undesirable       |
+----------------------------+--------------------------------+------------------------+--------------------------+
| Total Cholesterol          | < 200 mg/dL (<5.18 mmol/L)     | 200-239 mg/dL          | ≥ 240 mg/dL (≥6.22 mmol/L)|
| Triglycerides (Fasting)    | < 150 mg/dL (<1.70 mmol/L)     | 150-199 mg/dL          | ≥ 200 mg/dL (≥2.26 mmol/L)|
| HDL Cholesterol (Male)     | ≥ 40 mg/dL (≥1.04 mmol/L)      | ──                     | < 40 mg/dL (increased risk|
| HDL Cholesterol (Female)   | ≥ 50 mg/dL (≥1.30 mmol/L)      | ──                     | < 50 mg/dL (increased risk|
| LDL Cholesterol (Calculated)| < 100 mg/dL (<2.59 mmol/L)     | 130-159 mg/dL          | ≥ 160 mg/dL (≥4.14 mmol/L)|
| Non-HDL Cholesterol        | < 130 mg/dL (<3.37 mmol/L)     | 130-159 mg/dL          | ≥ 160 mg/dL (≥4.14 mmol/L)|
+---------------------------------------------------------------------------------------------------------+

Fasting vs. Non-Fasting Testing Guidelines

• Fasting Requirement: Traditionally, a strict 9 to 12-hour fast (water permitted; alcohol and medications restricted per clinical protocol) has been required prior to blood collection. Postprandial ingestion of dietary fat causes an acute influx of chylomicrons, which transiently elevates circulating triglycerides by 20% to 50% or more, distorting the VLDL-C estimate and invalidating the Friedewald calculation.
• Contemporary Non-Fasting Recommendations: Current clinical guidelines (AHA/ACC 2018/2019, ESC/EAS) permit non-fasting blood draws for initial routine cardiovascular risk screening in adults. Total Cholesterol and HDL-C fluctuate minimally (<2% to 5%) following standard meals, and calculated Non-HDL Cholesterol remains accurate. However, if a non-fasting triglyceride level exceeds 400 mg/dL, a repeat fasting lipid panel is mandatory to accurately evaluate basal triglycerides and calculate LDL-C.

Pre-Analytical Sources of Error

• Postural Effects & Hemoconcentration: Prolonged venous stasis from tourniquet application exceeding 1 minute, or drawing blood from an upright/standing patient who has not been seated for at least 5 minutes, induces an transcapillary fluid shift from the intravascular space into the interstitial fluid. Because large lipoprotein macromolecular complexes cannot cross the vascular endothelium, this causes hemoconcentration, falsely elevating Total Cholesterol, Triglycerides, and HDL-C concentrations by 5% to 15%.
• Collection Tubes (Serum vs. EDTA Plasma): Serum (red top or serum separator tube / SST) is the standard specimen in clinical laboratories. If EDTA plasma (lavender top) is collected, the hypertonic EDTA salt causes an osmotic fluid shift of water from erythrocytes into plasma, diluting plasma constituents and producing a 3% to 5% negative bias in measured lipid values. The CDC and National Reference System for Cholesterol standardized clinical reference cutoffs to serum; when EDTA plasma is analyzed, multiplying measured values by 1.03 converts them to serum equivalents.

---

Analytical Enzymatic Methods

Modern clinical chemistry laboratories employ automated, fully enzymatic multi-step colorimetric assays based on Trinder-type coupled reactions.

1. Total Cholesterol Assay (Allain et al. Method)

Because approximately 70% of circulating cholesterol exists as cholesteryl esters, total cholesterol quantification requires complete enzymatic hydrolysis followed by oxidation and chromogen coupling:

Step 1: Hydrolysis of Cholesteryl Esters
  Cholesteryl Esters + H2O ────(Cholesterol Esterase / CE)────► Free Cholesterol + Free Fatty Acids

Step 2: Oxidation of Free Cholesterol
  Free Cholesterol + O2 ────(Cholesterol Oxidase / CO)────► Cholest-4-en-3-one + H2O2

Step 3: Chromogenic Trinder Coupling Reaction
  2 H2O2 + 4-Aminoantipyrine (4-AAP) + Phenol ────(Peroxidase / POD)────► Quinoneimine Dye + 4 H2O
                                                                          (Magenta Chromogen,
                                                                           Absorbance ~500-520 nm)

Detailed Reaction Mechanics

1. Cholesterol Esterase (CE): Hydrolyzes fatty acid ester linkages at the C-3 position of cholesteryl esters, releasing free unesterified cholesterol and free fatty acids. Incomplete esterase activity causes significant negative analytical bias.
2. Cholesterol Oxidase (CO): Oxidizes the C-3 hydroxyl group of unesterified cholesterol while isomerizing the $\Delta^5$ double bond to a $\Delta^4$ position, producing cholest-4-en-3-one and equimolar hydrogen peroxide ($H_2O_2$).
3. Peroxidase (POD): Catalyzes the oxidative condensation of $H_2O_2$ with 4-aminoantipyrine (4-AAP) and a phenolic or substituted aniline hydrogen donor (e.g., phenol, 2,4-dichlorophenol, or TOOS) to form a pink-to-magenta quinoneimine dye. The absorbance at 500–520 nm is directly proportional to the total cholesterol concentration.

Analytical Interferences

• Ascorbic Acid (Vitamin C): As a potent reducing agent, ascorbic acid competes directly with the phenolic chromogen for $H_2O_2$, reducing peroxide to water without dye generation. This causes severe negative bias. Modern reagents incorporate ascorbate oxidase to pre-oxidize ascorbic acid to dehydroascorbate, eliminating interference.
• Bilirubin: Free and conjugated bilirubin cause negative interference above 5–10 mg/dL by competing with 4-AAP for $H_2O_2$ and reacting directly with quinoneimine dye intermediates.
• Hemolysis: Free hemoglobin consumes $H_2O_2$ via pseudoperoxidase activity and contributes background spectral absorbance at 500–540 nm.
• Reference Method: The Abell-Kendall method (developed by the CDC National Reference System for Cholesterol). Serum is saponified with alcoholic potassium hydroxide (KOH) at 50°C to hydrolyze esters, extracted with petroleum ether, and reacted with Liebermann-Burchard reagent (sulfuric acid and acetic anhydride) to generate a green chromophore measured spectrophotometrically at 620 nm.

2. Triglycerides Assay (Bucolo and David Method)

Enzymatic measurement of triglycerides couples bacterial lipase hydrolysis to a three-enzyme phosphorylation and oxidation cascade:

Step 1: Enzymatic Lipolysis
  Triglycerides + 3 H2O ────(Lipoprotein Lipase / LPL)────► Glycerol + 3 Free Fatty Acids

Step 2: Glycerol Phosphorylation
  Glycerol + ATP ────(Glycerol Kinase / GK, Mg2+)────► Glycerol-3-Phosphate + ADP

Step 3: Oxidation of Glycerol-3-Phosphate
  Glycerol-3-Phosphate + O2 ────(Glycerol Phosphate Oxidase / GPO)────► Dihydroxyacetone Phosphate (DHAP) + H2O2

Step 4: Peroxidase Trinder Chromogen Coupling
  H2O2 + 4-AAP + 4-Chlorophenol ────(Peroxidase / POD)────► Quinoneimine Dye + 2 H2O + HCl
                                                            (Absorbance ~500-540 nm)

Endogenous Free Glycerol & Glycerol Blanking (Pseudohypertriglyceridemia)

• The Biochemical Dilemma: The enzymatic reactions in Steps 2, 3, and 4 do not measure triglycerides directly; they quantify free glycerol. Standard automated triglyceride reagents assume that all glycerol measured was liberated from triglycerides by lipoprotein lipase in Step 1.
• Baseline Free Glycerol: Normal human serum contains a basal endogenous free glycerol concentration of 1.0 to 1.5 mg/dL (derived from normal adipocyte lipolysis), which corresponds to an apparent triglyceride overestimation of approximately 10 mg/dL. This small offset is clinically negligible and incorporated into standard reference intervals.
• Pseudohypertriglyceridemia: A clinically dangerous condition where serum contains markedly elevated concentrations of free glycerol unrelated to triglycerides, causing unblanked automated analyzers to report wildly elevated triglyceride results (ranging from 300 to >2000 mg/dL) in a completely crystal clear, non-lipemic serum sample:
  • Exogenous Glycerol Sources: Intravenous infusion of glycerol-containing therapeutics, notably total parenteral nutrition (TPN) with lipid emulsions (Intralipid), which contain 2.25% free glycerol as an isotonic stabilizer; intravenous nitroglycerin; or intravenous phenytoin formulated with propylene glycol/glycerol.
  • Endogenous Glycerol Sources: Severe diabetic ketoacidosis (massive uninhibited adipocyte lipolysis); acute ethanol ingestion; strenuous endurance exercise; acute critical liver necrosis; or Glycerol Kinase Deficiency (GKD), a rare X-linked inborn error of metabolism.
• Analytical Solution (Glycerol Blanking):
  • In a glycerol-blanked assay, the automated analyzer uses a two-reagent format. Reagent 1 contains GK, GPO, POD, and chromogen, but omits lipoprotein lipase. It reacts with and quantifies the pre-existing free glycerol, establishing a blank baseline absorbance.
  • Reagent 2 then introduces microbial Lipoprotein Lipase, hydrolyzing true triglycerides to generate newly liberated glycerol. The instrument calculates true triglyceride concentration by subtracting the blank absorbance from the final total absorbance:

$\text{True Triglycerides} = \text{Total Glycerol (Post-Lipase)} - \text{Endogenous Free Glycerol (Pre-Lipase)}$

3. High-Density Lipoprotein Cholesterol (HDL-C) Assays

Historical Chemical Precipitation Methods

Prior to the late 1990s, HDL-C measurement required a manual, off-line precipitation step:

• Reagents containing polyanions and divalent cations (e.g., Dextran Sulfate (50 kDa) with $Mg^{2+}$, Heparin with $Mn^{2+}$, or Sodium Phosphotungstate with $Mg^{2+}$) were added to serum.
• The divalent cations neutralize the negative surface charges on Apo B-containing lipoproteins (chylomicrons, VLDL, IDL, and LDL), forming insoluble, heavy complexes that aggregate and precipitate upon centrifugation at 1500–2000 $\times$ g for 15 minutes.
• The supernatant—containing exclusively soluble HDL particles—was aspirated and analyzed using standard enzymatic total cholesterol reagents.
• Major Limitation: When serum Triglycerides exceed 400 mg/dL, Apo B-containing particles do not sediment completely; they float or remain suspended, producing a turbid supernatant and falsely elevating measured HDL-C.

Modern Direct / Homogeneous HDL-C Assays

Modern automated analyzers utilize homogeneous assays that eliminate off-line centrifugation using a two-reagent liquid system:

1. Selective Detergent / Accelerator Method:
   • Reagent 1: Contains polyanions (e.g., cyclodextrin or dextran sulfate) and a synthetic polymer/surfactant that selectively binds and blocks non-HDL lipoproteins (LDL, VLDL, chylomicrons), shielding their cholesterol from enzymatic consumption.
   • Reagent 2: Introduces a specific non-ionic surfactant that selectively solubilizes HDL particles, enabling cholesterol esterase and cholesterol oxidase to react specifically with HDL cholesterol, producing quinoneimine dye proportional to HDL-C.
2. Immunoinhibition Method: Reagent 1 contains specific anti-human Apo B antibodies that bind and cross-link all non-HDL particles; the enzymatic reagent added in Step 2 reacts solely with unhindered HDL.

---

The Friedewald Calculation

In 1972, William T. Friedewald, Robert I. Levy, and Donald S. Fredrickson published an empirical mathematical formula to estimate Low-Density Lipoprotein Cholesterol (LDL-C) without requiring expensive and labor-intensive preparative ultracentrifugation.

Mathematical Formulation

$\text{In mg/dL: } \text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \left(\frac{\text{Triglycerides}}{5}\right)$

$\text{In mmol/L: } \text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \left(\frac{\text{Triglycerides}}{2.2}\right)$

Physiological Derivation

1. Total circulating plasma cholesterol is distributed across the major lipoprotein fractions:

$\text{Total Cholesterol} = \text{HDL-C} + \text{LDL-C} + \text{VLDL-C} + \text{Chylomicron-C} + \text{IDL-C}$

1. In a healthy individual following an overnight 9 to 12-hour fast, chylomicrons are cleared completely, and IDL exists in negligible concentrations. The mass balance equation simplifies to:

$\text{Total Cholesterol} = \text{HDL-C} + \text{LDL-C} + \text{VLDL-C}$

1. Rearranging to solve for LDL-C yields:

$\text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \text{VLDL-C}$

1. In normal fasting plasma, VLDL particles maintain a relatively stable triglyceride-to-cholesterol mass ratio of approximately 5:1 (meaning that for every 5 mg of triglycerides in VLDL, there is 1 mg of cholesterol). Therefore, VLDL-C can be estimated from total triglyceride concentration:

$\text{Estimated VLDL-C} = \frac{\text{Triglycerides}}{5} \quad \text{(in mg/dL)}$

$\text{Estimated VLDL-C} = \frac{\text{Triglycerides}}{2.2} \quad \text{(in mmol/L)}$

+-------------------------------------------------------------------------------------------------------------+
|                          Example Calculation using the Friedewald Equation (mg/dL)                          |
+-------------------------------------------------------------------------------------------------------------+
| Laboratory Results:                                                                                         |
|   Total Cholesterol = 220 mg/dL                                                                             |
|   HDL Cholesterol   = 45 mg/dL                                                                              |
|   Triglycerides     = 150 mg/dL                                                                             |
|                                                                                                             |
| Step 1: Calculate VLDL-C = TG / 5 = 150 / 5 = 30 mg/dL                                                      |
| Step 2: Calculate LDL-C  = TC - HDL-C - VLDL-C = 220 - 45 - 30 = 145 mg/dL                                 |
+-------------------------------------------------------------------------------------------------------------+

The Three Strict Limitations Where Friedewald Fails (ASCP Exam Core)

The medical laboratory technologist MUST NEVER REPORT a calculated Friedewald LDL-C under any of the following three clinical conditions:

+-------------------------------------------------------------------------------------------------------------+
|                                 The Three Strict Friedewald Contraindications                               |
+-------------------------------------------------------------------------------------------------------------+
| Condition                   | Mechanism of Failure                      | Laboratory Action Required         |
+-----------------------------+-------------------------------------------+------------------------------------+
| 1. Triglycerides > 400 mg/dL| TG:Cholesterol ratio in VLDL exceeds 5:1; | Suppress calculated LDL-C;         |
|    (>4.52 mmol/L)           | VLDL-C is grossly overestimated, causing  | Reflex to Direct LDL-C Assay or    |
|                             | severe false UNDERESTIMATION of LDL-C.    | report as "Uncalculable".          |
+-----------------------------+-------------------------------------------+------------------------------------+
| 2. Presence of Chylomicrons | Chylomicrons have a TG:cholesterol ratio  | Require repeat 12-hour fasting     |
|    (Non-fasting state /     | of 10:1 to 20:1; formula misinterprets    | specimen or perform Direct LDL-C   |
|    Type I or Type V)        | chylomicron TG as VLDL, falsely lowering  | assay.                             |
|                             | calculated LDL-C.                         |                                    |
+-----------------------------+-------------------------------------------+------------------------------------+
| 3. Dysbetalipoproteinemia   | Beta-VLDL and IDL remnants accumulate with| Suppress Friedewald; perform       |
|    (Fredrickson Type III)   | an abnormal cholesterol-rich 1:1 TG:chol  | Direct LDL-C, Beta-quantification, |
|                             | ratio; dividing TG by 5 wildly fails.     | or Apo B-100 testing.              |
+-----------------------------+-------------------------------------------+------------------------------------+

What to Do When Friedewald is Invalid

When calculated LDL-C is contraindicated, the laboratory must use alternative diagnostic strategies:

1. Direct Homogeneous LDL-C Assays: Employs selective detergents that solubilize and clear non-LDL particles in Step 1, followed by a second detergent that selectively dissolves LDL particles for enzymatic color development in Step 2. These assays remain analytically valid up to Triglycerides of 1000 mg/dL.
2. Preparative Ultracentrifugation ($\beta$-Quantification Reference Method): The gold standard method established by the CDC. Serum is adjusted to a density of 1.006 g/mL and ultracentrifuged at 105,000 $\times$ g for 18 hours. Chylomicrons and VLDL float to the top and are sliced off. The bottom infranatant (containing LDL and HDL) is collected; its cholesterol is measured, and HDL-C (measured after heparin-Mn$^{2+}$ precipitation) is subtracted to determine true LDL-C.
3. Modern Empirical Equations:
   • Martin-Hopkins Equation: Replaces the fixed divisor 5 with an adjustable divisor (ranging from 3.1 to 11.9) based on a 180-cell lookup table stratified by the patient's exact triglyceride and non-HDL cholesterol levels. Significantly improves accuracy at low LDL-C (<70 mg/dL) and moderate hypertriglyceridemia (150–400 mg/dL).
   • Sampson (NIH) Equation: An advanced polynomial equation derived by the National Institutes of Health that accurately calculates LDL-C in patients with Triglycerides up to 800 mg/dL.

---

Non-HDL Cholesterol: Clinical Role and Calculations

Non-HDL Cholesterol is calculated by subtracting HDL Cholesterol from Total Cholesterol:

$\text{Non-HDL Cholesterol} = \text{Total Cholesterol} - \text{HDL-C}$

Clinical and Physiological Rationale

• Comprehensive Atherogenic Particle Capture: Non-HDL cholesterol captures the total cholesterol content of all atherogenic, Apolipoprotein B-containing lipoproteins combined, including LDL, VLDL, Intermediate-Density Lipoproteins (IDL), Lipoprotein(a), and remnant lipoproteins.
• Key Diagnostic Advantages:
  1. No Fasting Required: Postprandial triglyceride fluctuations do not invalidate Non-HDL cholesterol because dietary chylomicrons contribute negligibly to total cholesterol.
  2. Valid at Extreme Triglyceride Levels: Because it does not rely on triglyceride-based VLDL estimation, Non-HDL cholesterol remains 100% accurate and reportable when Triglycerides exceed 400 mg/dL, avoiding the Friedewald breakdown.
  3. Zero Added Reagent Cost: It is calculated directly from routine Total Cholesterol and HDL-C measurements.
• Treatment Targets: National and international cardiovascular guidelines establish Non-HDL cholesterol as a primary secondary target of therapy, particularly in patients with diabetes mellitus, metabolic syndrome, obesity, or hypertriglyceridemia. In all risk tiers, the Non-HDL cholesterol target is set at exactly 30 mg/dL higher than the corresponding LDL-C goal (reflecting normal VLDL-C of ~30 mg/dL; e.g., if LDL-C goal is <70 mg/dL, the Non-HDL-C target is <100 mg/dL).